Research & Clinical Summary

Dr. Chapuis’ translational research laboratory is developing novel ways to modulate the immune system to target cancer. Her research is especially focused on 1) understanding the factors associated with successful “adoptive” transfer of immune T cells and improving the therapeutic efficacy of both natural (native) and gene-modified T cells targeting viral and tumor antigens, and 2) developing methods that improve the survival, proliferation and anti-tumor activity of infused T cells so as to better eliminate tumor targets. These advances are in turn used to 3) develop clinical strategies to optimally activate therapeutic T cells to specifically eliminate cancer in patients, without the noxious side effects of chemotherapy

Publications

The following publications were retrieved from PubMed:

Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C,
“T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.”
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34.31 (2016 Nov 1): 3787-3795.

Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C,
“Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8⁺ T Cells In Vivo.”
Science immunology 2.8 (2017 Feb): .

Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD,
“A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.”
Blood 130.22 (2017 Nov 30): 2410-2419.

Paulson KG, Park SY, Vandeven NA, Lachance K, Thomas H, Chapuis AG, Harms KL, Thompson JA, Bhatia S, Stang A, Nghiem P,
“Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics.”
Journal of the American Academy of Dermatology 78.3 (2018 Mar): 457-463.e2.

Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem HP, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ,
“Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.”
Blood 133.15 (2019 Apr 11): 1652-1663.

Paulson KG, Lahman MC, Chapuis AG, Brownell I,
“Immunotherapy for skin cancer.”
International immunology 31.7 (2019 Jul 13): 465-475.

Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ,
“The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.”
Blood 133.17 (2019 Apr 25): 1876-1887.

Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, Voillet V, Gottardo R, Ragnarsson GB, Bleakley M, Yeung CC, Muhlhauser P, Nguyen HN, Kropp LA, Castelli L, Wagener F, Hunter D, Lindberg M, Cohen K, Seese A, McElrath MJ, Duerkopp N, Gooley TA, Greenberg PD,
“T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.”
Nature medicine 25.7 (2019 Jul): 1064-1072.

Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, Wojcik K, Chapuis AG, Thompson JA, Madeleine MM, Gardner JM,
“Age-Specific Incidence of Melanoma in the United States.”
JAMA dermatology 156.1 (2020 Jan 1): 57-64.

Jing L, Ott M, Church CD, Kulikauskas RM, Ibrani D, Iyer JG, Afanasiev OK, Colunga A, Cook MM, Xie H, Greninger AL, Paulson KG, Chapuis AG, Bhatia S, Nghiem P, Koelle DM,
“Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8⁺ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.”
Cancer immunology research 8.5 (2020 May): 648-659.

Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Jamieson AW, Bar M, Cassaday RD, Chapuis AG, Cowan AJ, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ,
“Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.”
Blood 137.3 (2021 Jan 21): 323-335.

Ecsedi M, McAfee MS, Chapuis AG,
“The Anticancer Potential of T Cell Receptor-Engineered T Cells.”
Trends in cancer 7.1 (2021 Jan): 48-56.

Wright JH, Huang LY, Weaver S, Archila LD, McAfee MS, Hirayama AV, Chapuis AG, Bleakley M, Rongvaux A, Turtle CJ, Chanthaphavong RS, Campbell JS, Pierce RH,
“Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry.”
Journal of immunological methods 492. (2021 May): 112955.

Lahman MC, Paulson KG, Nghiem PT, Chapuis AG,
“Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.”
The Journal of investigative dermatology 141.8 (2021 Aug): 1897-1905.

Iovino L, Thur LA, Gnjatic S, Chapuis A, Milano F, Hill JA,
“Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.”
Journal for immunotherapy of cancer 9.5 (2021 May): .